Rapid communication: Acute renal failure associated with tenofovir: Evidence of drug-induced nephrotoxicity

American Journal of the Medical Sciences

Volumn 324, Issue 6, 2002, Pages 342-344

  Coca, Steven ^a   Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute renal failure; AIDS; Antiviral therapy; HIV; Tenofovir

Indexed keywords

ADEFOVIR; CIDOFOVIR; TENOFOVIR; TENOFOVIR DISOPROXIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CLEARANCE; KIDNEY FAILURE; MALE; NEPHROTOXICITY;

EID: 0036953640     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200212000-00011     Document Type: Article

References (13)

1. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-63.
2. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001;45:2733-9.
3. Lalezari JP. Cidofovir: a new therapy for cytomegalovirus retinitis. J Acqur Immune Defic Syndr Hum Retroviral 1997; 14:S22-S26.
4. Lalezari JP, Kuppermann BD. Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. J Acqur Immune Defic Syndr Hum Retrovirol 1997;14:S27-S31.
5. Anonymous. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med 1997;126:264-74.
6. Lalezari JP. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acqur Immune Defic Syndr Hum Retrovirol 1998;17:339-44.
7. Meier P, Dautheville-Guibal S, Ronco PM, et al. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002;17:148-9.
8. Cundy KC, Barditch-Crovo P, Walker RE, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1995;39:2401-5.
9. Fisher E, Brosgart C, Cohn D, et al. Safety of adefovir dipivoxil (ADV) and incidence of proximal renal tubular disorder (PRTD) in a placebo (PLC)-controlled trial in patients (Pt) with advanced HIV disease. [Abstract 678]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, Illinois. Alexandria (VA): Foundation for Retrovirology and Human Health; 1999.
10. Ho ES, Lin DC, Mendel DB, et al. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000;11:383-93.
11. Cihlar T, Lin DC, Pritchard JB, et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999;56:570-80.
12. Roch-Ramel F. Renal transport of organic anions. Curr Opin Nephrol Hypertens 1998;7:517-24.
13. Sweet D, Wolff N, Pritchard J. Expression cloning and characterization of ROAT1. J Biol Chem 1997;272:30088-95.